RxDoctor Payments Data

Edward Leonard, MD

Infectious Disease · Bellevue, WANPI 1407874795

Payments from drug & device makers

$702in general payments, 2019–2025

Across 27 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$221
  • Astellas Pharma US Inc$128
  • Merck$97
  • Gilead$92
  • Viiv Healthcare Company$62
  • Aimmune Therapeutics, Inc.$47
  • plus $55 from 2 others

What the payments were for

  • Food & beverage$61087%
  • Education$9313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702 in reported general payments places this provider in the 65th percentile of 186 infectious disease providers in Washington.

See all infectious disease providers in Washington

Medicare billing

Part B allowed, 2024
$67,194
Medicare patients
195
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala64$272,173
JulucaDolutegravir/Rilpivirine13$46,572
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$42,917
DovatoDolutegravir Sodium/Lamivudine12$40,725
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$40,694
Cephalexin72$3,313
CeftriaxoneCeftriaxone Sodium16$2,829
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine13$2,612
Vancomycin Hcl25$2,083
Doxycycline Hyclate18$1,415
Methenamine Hippurate16$958
Estradiol17$952
Doxycycline Monohydrate22$867
Oxycodone Hcl16$780
Azithromycin31$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$92$315,09075 claims
Viiv Healthcare CompanyJuluca, Dovato$62$87,29725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 186 infectious disease providers in Washington.

Other infectious disease in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →